Merck & Co.
AWARDS
NEWS
Asher Bio began two years ago and raised $55 million in a Series A financing round this March to take forward a series of engineered cytokines that aim to eliminate both the toxicities and the loss of efficacy in immunotherapy.
The study of Molnupiravir will assess 1,300 adult participants 18 and over who cohabitate with someone who has tested positive for the coronavirus and is symptomatic.
Approximately 14,000 American women are expected to be diagnosed with invasive cervical cancer in 2021, and more than 4,000 are expected to succumb to the disease.
Merck has announced its vaxneuvance for pneumococcal disease in infants and has met key safety, tolerability, and immunogenicity endpoints in the first 30 days.
Atavistik Bio is linking a deep understanding of metabolite-protein interactions and their potential to lead to novel drugs that will restore protein function in metabolic diseases and cancers.
Merck’s Welireg won FDA approval for adult patients with von Hippel-Lindau disease who require therapy for associated RCC, central nervous system, and hemangioblastomas.
JOBS
IN THE PRESS